CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 106 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $372,750 | +36.2% | 25,000 | 0.0% | 0.01% | +37.5% |
Q2 2023 | $273,750 | +25.6% | 25,000 | 0.0% | 0.01% | +14.3% |
Q1 2023 | $218,000 | +39.1% | 25,000 | 0.0% | 0.01% | +40.0% |
Q4 2022 | $156,750 | +78.1% | 25,000 | 0.0% | 0.01% | +25.0% |
Q3 2022 | $88,000 | +18.9% | 25,000 | 0.0% | 0.00% | +33.3% |
Q2 2022 | $74,000 | -5.1% | 25,000 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $78,000 | -8.2% | 25,000 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $85,000 | -53.6% | 25,000 | -50.0% | 0.00% | -66.7% |
Q3 2021 | $183,000 | +64.9% | 50,000 | +100.0% | 0.01% | +50.0% |
Q2 2021 | $111,000 | -2.6% | 25,000 | 0.0% | 0.01% | 0.0% |
Q1 2021 | $114,000 | -20.8% | 25,000 | 0.0% | 0.01% | -33.3% |
Q4 2020 | $144,000 | +61.8% | 25,000 | 0.0% | 0.01% | +50.0% |
Q3 2020 | $89,000 | +2.3% | 25,000 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $87,000 | +135.1% | 25,000 | 0.0% | 0.01% | +75.0% |
Q1 2020 | $37,000 | -24.5% | 25,000 | 0.0% | 0.00% | +33.3% |
Q4 2019 | $49,000 | – | 25,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |